Sawyer & Company Inc Lowers Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Sawyer & Company Inc lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,476 shares of the company’s stock after selling 906 shares during the quarter. Johnson & Johnson comprises about 1.7% of Sawyer & Company Inc’s holdings, making the stock its 17th largest position. Sawyer & Company Inc’s holdings in Johnson & Johnson were worth $3,993,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in JNJ. Hibernia Wealth Partners LLC acquired a new stake in Johnson & Johnson in the third quarter valued at about $27,000. FNY Investment Advisers LLC acquired a new stake in Johnson & Johnson in the third quarter valued at about $37,000. Tower View Wealth Management LLC lifted its position in Johnson & Johnson by 183.3% in the third quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 165 shares during the period. Creative Capital Management Investments LLC lifted its position in shares of Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after acquiring an additional 86 shares during the period. Finally, VitalStone Financial LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at approximately $48,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, EVP Jennifer L. Taubert sold 59,397 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now directly owns 4,099,575 shares of the company’s stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $157.96 on Thursday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $380.65 billion, a price-to-earnings ratio of 11.44, a PEG ratio of 2.62 and a beta of 0.53. The firm’s fifty day simple moving average is $158.76 and its 200 day simple moving average is $156.69. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The firm had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same quarter in the previous year, the business posted $2.35 EPS. The firm’s revenue was down 9.7% compared to the same quarter last year. As a group, equities research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th were issued a $1.19 dividend. The ex-dividend date of this dividend was Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. Johnson & Johnson’s dividend payout ratio is currently 34.47%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $170.00 to $163.00 in a research note on Wednesday, December 13th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, March 13th. Finally, UBS Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $180.00 in a research note on Friday, December 1st. Seven analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $177.31.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.